Riskpilot← Back to searchSign inGet full accessENKAM PHARMACEUTICALS ApS
APSBankruptCVR 25812921Fruebjergvej 3Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 20001 employees
Revenue 2018
DKK -276K
+15% vs 2017
EBITDA margin
106.0%
-6% vs 2017
Equity ratio
-15213.1%
Financial strength
Net profit 2018
DKK -294K
-6% vs 2017
| Revenue | DKK -276K | +15% |
| EBITDA | DKK -292K | -6% |
| Net profit | DKK -294K | -6% |
| Total assets | DKK 8K | -63% |
| Equity | DKK -1,2M | -33% |
| Employees | 1 | — |
Legal name
ENKAM PHARMACEUTICALS ApS
CVR number
25812921
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
12. december 2000
Share capital
DKK 73.756.916
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2018-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Fruebjergvej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | -1.060 | -2.621 | 4.669 | -426 | -272 | -239 | -276 |
| Staff expenses | -2.342 | -2.275 | -1.862 | -66 | -51 | -37 | -17 |
| EBITDA | -3.403 | -4.896 | 2.807 | -492 | -323 | -276 | -292 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3.403 | -4.896 | 2.807 | -492 | -323 | -276 | -292 |
| Net financials | -10 | 9 | 6 | 30 | -22 | -1 | -1 |
| Profit before tax | -1.639 | -4.887 | 2.812 | -462 | -345 | -277 | -294 |
| Tax | 887 | -1.222 | -0 | 26 | -0 | -0 | -0 |
| Net profit | -2.526 | -3.665 | 2.812 | -488 | -345 | -277 | -294 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
| Total assets | 3.267 | 6.657 | 1.281 | 526 | 146 | 21 | 8 |
| Equity | -3.459 | -4.730 | -1.918 | -263 | -608 | -886 | -1.179 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6.726 | 11.388 | 2.659 | 790 | 755 | 907 | 1.187 |
| Total debt | 6.726 | 11.388 | 2.659 | 790 | 755 | 907 | 1.187 |
EBITDA margin
-29225600.0%
This company
15.8%
Market median
-184972252% vs market
20122018
Equity ratio
-15213.1%
This company
38.2%
Market median
-39925% vs market
20122018
Return on equity
-29366500.0%
This company
18.4%
Market median
-159600643% vs market
20122018
Net profit margin
-29366500.0%
This company
8.1%
Market median
-362549483% vs market
20122018
Asset turnover
-35.57×
This company
1.12×
Market median
-3276% vs market
20122018
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20122018
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
VS Founder | Founder | 2000 | — | — |
AV Founder | Founder | 2000 | — | — |
MA Management | Management | 2000 | — | — |
SL Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
LC Founder | Founder | 2000 | — | — |
FM Founder | Founder | 2000 | — | — |
MO Founder | Founder | 2000 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2005 | — | — | |
| Board of Directors | 2003 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2009 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2005 | — | — | |
| Chairman | 2001 | — | — | |
| Chairman | 2009 | — | — | |
| Board of Directors | 2000 | — | — | |
| Board of Directors | 2008 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5.0% | 5.0% | 2015 | |
| Individual | 90.0% | 90.0% | 2007 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ENKAM PHARMACEUTICALS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vladyslav Soroka | Founder | 0 companies |
| Arne Valdemar Holm | Founder | 0 companies |
| Morten Albrechtsen | Management | 0 companies |
| Sven-Erik Lennart Nilsson | Chief Executive Officer | 0 companies |
| Lars Christian Biilmann Rønn | Founder | 0 companies |
| Flemming Martin Poulsen | Founder | 0 companies |
| Marianne Olsen | Founder | 0 companies |
| Robert George Mansfield | Chairman | 0 companies |
| Jan Quistgaard | Board of Directors | 0 companies |
| Peter Holme Jensen | Board of Directors | 0 companies |
| Jan-Eric Østerlund | Board of Directors | 0 companies |
| Jan Evert Lilja | Board of Directors | 0 companies |
| Jan-Eric Østerlund | Board of Directors | 0 companies |
| Sven Dyrløv Madsen | Chairman | 0 companies |
| Robert George Mansfield | Chairman | 0 companies |
| Elisabeth Marianne Bock | Board of Directors | 0 companies |
| Volodymyr Berezin | Board of Directors | 0 companies |